PD-1/PD-L1受体抑制剂与肾癌免疫治疗的研究进展  

Progression of PD-1/PD-L1 inhibitors and renal cell carcinoma immunothreapy

作　　者：张晓敏[1] 胡泓[1] 潘宏铭[1] ZHANG Xiaomin HU Hong PAN Hongming.(Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China)

机构地区：[1]浙江大学医学院附属邵逸夫医院肿瘤内科,杭州310016

出　　处：《临床肿瘤学杂志》2017年第1期75-80,共6页Chinese Clinical Oncology

基　　金：国家自然科学基金资助项目(81272593;81572592);浙江省自然基金重点资助项目(LZ15H160001);杭州市卫生科技计划一般项目(2015A53)

摘　　要：肾癌对放化疗均不敏感,现有治疗手段难以取得理想效果,亟需探究新的治疗方法。程序性死亡因子1(PD-1)和程序性死亡因子配体1(PD-L1)是一对免疫共刺激因子,PD-1、PD-L1高表达与肿瘤免疫治疗及预后密切相关。PD-1及PD-L1阻滞剂在恶性黑色素瘤、非小细胞肺癌的治疗中已取得显著成效,在其他恶性肿瘤中的疗效亦在不断研究中。相关临床研究显示抗PD-1/PD-L1治疗在肾癌中显现一定疗效。PD-1/PD-L1阻滞剂有望成为肾癌治疗的新希望。本文旨在回顾及总结近年来PD-1及PD-L1阻滞剂在肾癌中的应用及研究进展,并探讨其可能的分子机制。New therapeutic methods for renal carcinoma are in urgent need because of its insensitivity to the existing treat- ments, radiotherapy and chemotherapy. Programmed cell death factor 1 （PD-1） and programmed cell death factor ligand 1 （PD-L1） are costimulatory factors. Anti-PD-1 and anti-PD-L1 therapies are proved to be effective among the treatments for malignant melanoma and non-small cell lung cancer. Moreover, they are widely used to other malignancies as well. PD-I/PD-L1 inhibitors are expected to become new methods for the treatment of renal cell carcinoma. This article aims to review the research progressions of PD-1/PD-L1 im- mune checkpoint inhibitors in renal cell carcinoma and explore the possible molecular mechanisms.

关 键 词：肾癌 程序性死亡因子1(PD-1) 程序性死亡因子配体1(PD-L1) 免疫检查点阻滞剂 

分 类 号：R737.11[医药卫生—肿瘤]